AB821 is a CD8+ T cell selective IL-21 with enhanced bioavailability that reduces CD8+ T cell exhaustion to induce potent antitumor activity
Renee Greer PhD, Arisa Paul MSc, Manu Kumar PhD, Jeffrey Houser, Paul Mesko, Meghana Sukthankar, Wei Wei Prior PhD, Rose Banzon, Audrey Hollingsworth, Ruth Lan PhD, Ivana Djuretic PhD, Andy Yeung PhD
An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
David R. Spigel MD, Constantine Albany MD, Michael Chisamore PhD, Kelly D. Moynihan PhD, Christopher DelNagro, PhD, Matt Axt, Xiaohan Liu Pharm D, Mark Sayles MD, PhD, Andrea Pirzkall MD, Elizabeth I. Buchbinder MD
CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus
Matteo Iannacone, MD, PhD
CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus
Matteo Iannacone, MD, PhD
An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
Elizabeth I Buchbinder, MD, David R Spigel, MD, Constantine Albany, MD, Michael Chisamore, PhD, Kelly D Moynihan, PhD, Xiaohan Liu, Pharm D, Christopher DelNagro PhD, Matt Axt, Andrea Pirzkall, MD
Engineered cell surface tag-targeted IL-2 and IL-21 selectively and safely enhance CAR-T anti-tumor activity via different mechanisms
Nathan D Mathewson, PhD, Wei Chen, PhD, Paul Bessette, PhD, Sara Sleiman, MD, Meghana Sukthankar, Kelly D Moynihan, PhD, Chris Kimberlin, PhD, Terrence Park, Audrey Hollingsworth, Saar Gill, MD, PhD, Andy Yeung, PhD, Ivana Djuretic, PhD
Selective support of CAR-T cell therapies by cis-targeted IL-2 or IL-21 cytokines results in enhanced anti-tumor activity
Sara Sleiman, MD, Nathan D Mathewson, PhD, Feng Shen, MD, PhD, Kelly Moynihan, PhD, Wei Chen, PhD, Paul Bessette, PhD, Chris Kimberlin, PhD, Danielle Pappas, Terrence Park, Andy Yeung, PhD, Ivana Djuretic, PhD and Saar Gill, MD, PhD
AB821 is a CD8+ T-cell selective IL-21 with enhanced bioavailability that mediates potent antitumor activity, cytotoxicity, and expansion of memory CD8+ T cells
Renee Greer PhD, Henry Nguyen PhD, Paul Mesko, Wei Wei Prior, Arisa Paul, Manu Kumar PhD, Hussein Sultan PhD, Meghana Sukthankar, Irene Ni, Mike Chin, Kelly D. Moynihan PhD, Ruth Lan PhD, Ton N. Schumacher PhD, Robert D. Schreiber PhD, Ivana Djuretic PhD, Andy Yeung PhD
The CD8+ T cell selectivity of AB248 is essential for optimal anti-tumor activity and safety in nonclinical models
Kelly D. Moynihan PhD; Danielle Pappas; Manu Kumar PhD; Terrence Park; Jessie Chen; Ruth Lan PhD; Irene Ni; Paul Bessette PhD; Henry Nguyen PhD; Christopher Kimberlin PhD; Yonghee Lee; Cinthia Millan PhD; Mike Chin; Hussein Sultan PhD; Ton N. Schumacher PhD; Robert D. Schreiber PhD; Andy Yeung PhD; Ivana Djuretic PhD
Selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity in a hepatitis B virus (HBV) model
Kelly D. Moynihan PhD, Francesco Andreata PhD, Pietro Di Lucia, Danielle Pappas, Irene Ni, Paul Bessette PhD, Henry Nguyen PhD, Christopher Kimberlin PhD, Yonghee Lee, Cinthia Millan PhD, Mike Chin, Andy Yeung PhD, Craig Gibbs PhD, Ivana Djuretic PhD, Matteo Iannacone PhD
AB248 is a CD8+ T cell selective IL-2 designed for superior safety and anti-tumor efficacy
Kelly D. Moynihan PhD, Danielle Pappas, Terrence Park, Wei Chen PhD, Irene Ni, Paul Bessette PhD, Henry Nguyen PhD, Mike Chin, Ruth Lan PhD, Aaron Arvey PhD, Ton N. Schumacher PhD, Andy Yeung PhD, Ivana Djuretic PhD
Selective activation of CD8+ T cells by a CD8-targeted IL-21 results in enhanced anti-tumor efficacy and safety
Renee Greer PhD, David Liu PhD, Henry Nguyen PhD, Wei Wei Prior, Meghana Sukthankar, Paul Mesko, Jeffrey Houser, Irene Ni, Mike Chin, Kelly D. Moynihan PhD, Ton N. Schumacher PhD, Ruth Lan, PhD, Ivana Djuretic PhD, Andy Yeung PhD
CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy
Nathan D. Mathewson PhD, Kelly D. Moynihan PhD, Sara Sleiman PhD, Wei Chen PhD, Paul Bessette PhD, Chris Kimberlin PhD, Danielle Pappas, Terrence Park, Eric Wigton PhD, Saar Gill PhD, Andy Yeung PhD, Ivana Djuretic PhD
Engineering cis-targeted immunomodulators to enhance their selectivity and effectiveness as therapeutics
Andy Yeung, PhD
CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines
Hussein Sultan, PhD, Kelly Moynihan, PhD, Yuang Song, Ton Schumacher, PhD, Andy Yeung, PhD, Ivana Djuretic, PhD, and Robert D. Schreiber, PhD
Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety
Kelly Moynihan, PhD, Danielle Pappas, Terrence Park, Wei Chen PhD, Irene Ni, Paul Bessette PhD, Mike Chin, Ton Schumacher, PhD, Andy Yeung, PhD, and Ivana Djuretic, PhD
This links to an external website.